Format

Send to

Choose Destination
Blood. 2012 Jan 5;119(1):180-7. doi: 10.1182/blood-2011-08-374561. Epub 2011 Nov 7.

Tcl1 interacts with Atm and enhances NF-κB activation in hematologic malignancies.

Author information

1
Department of Molecular Immunology, Virology and Medical Genetics, The Ohio State University, Columbus, OH 43210, USA.

Abstract

The T-cell leukemia/lymphoma 1 (TCL1) oncogene is a target of chromosomal translocations and inversions at 14q31.2, and its rearrangement in T cells causes T-cell prolymphocytic leukemias. TCL1 dysregulation in B cells is responsible for the development of an aggressive form of chronic lymphocytic leukemia (CLL), the most common human leukemia. We have investigated the mechanisms underlying the oncogenic functions of Tcl1 protein using a mass spectrometry approach and have identified Atm (ataxia-telangiectasia mutated) as a candidate Tcl1-interacting protein. The Tcl1-Atm complex formation was validated by coimmunoprecipitation experiments. Importantly, we show that the association of Atm with Tcl1 leads to enhanced IκBα phosphorylation and ubiquitination and subsequent activation of the NF-κB pathway. Our findings reveal functional cross-talk between Atm and Tcl1 and provide evidence for a novel pathway that could be targeted in leukemias and lymphomas.

PMID:
22065599
PMCID:
PMC3251228
DOI:
10.1182/blood-2011-08-374561
[Indexed for MEDLINE]
Free PMC Article

Publication types, MeSH terms, Substances, Grant support

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center